NOX 7.53% 8.6¢ noxopharm limited

Ann: Noxopharm Corporate Presentation, page-5

  1. 1,216 Posts.
    lightbulb Created with Sketch. 1375
    Novartis drug is already approved. They are currently focusing on distribution and undertaking other studies to increase market share in the current treatable population. As I understand, Novartis are still interested in having their treatment offered earlier in the treatment process, which may open the door for Veyonda at some point in the future. Looks like a interesting 3rd and 4th quarter for holders.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
8.6¢
Change
-0.007(7.53%)
Mkt cap ! $25.13M
Open High Low Value Volume
9.2¢ 9.2¢ 8.3¢ $35.92K 415.3K

Buyers (Bids)

No. Vol. Price($)
2 7364 8.5¢
 

Sellers (Offers)

Price($) Vol. No.
9.4¢ 90189 1
View Market Depth
Last trade - 11.53am 15/08/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.